New pill tested to tame debilitating bowel disease

NCT ID NCT05291689

Summary

This study tested an oral drug called MORF-057 in 39 adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The main goal was to see if the drug was safe, tolerable, and could reduce disease activity over 12 weeks of treatment. Participants who completed the initial study had the option to continue treatment in a longer-term extension study.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Study Site

    Tampa, Florida, 33609, United States

  • Clinical Study Site

    Lafayette, Louisiana, 70503, United States

  • Clinical Study Site

    Freehold, New Jersey, 07728, United States

  • Clinical Study Site

    Brooklyn, New York, 11235, United States

  • Clinical Study Site

    New York, New York, 10075, United States

  • Clinical Study Site

    Bydgoszcz, 85-794, Poland

  • Clinical Study Site

    Elblag, 82-300, Poland

  • Clinical Study Site

    Katowice, 40-748, Poland

  • Clinical Study Site

    Lodz, 90-349, Poland

  • Clinical Study Site

    Lodz, 90-752, Poland

  • Clinical Study Site

    Oświęcim, 32-600, Poland

  • Clinical Study Site

    Sopot, 81-756, Poland

  • Clinical Study Site

    Sosnowiec, 41-209, Poland

  • Clinical Study Site

    Staszów, 28-200, Poland

  • Clinical Study Site

    Tychy, 43-100, Poland

  • Clinical Study Site

    Warsaw, 00-728, Poland

  • Clinical Study Site

    Warsaw, 02-665, Poland

Conditions

Explore the condition pages connected to this study.